West Pharmaceutical Services, Inc. (WST)
| Market Cap | 24.37B +32.8% |
| Revenue (ttm) | 3.33B +12.4% |
| Net Income | 564.90M +15.8% |
| EPS | 7.81 +16.8% |
| Shares Out | 70.38M |
| PE Ratio | 44.34 |
| Forward PE | 37.31 |
| Dividend | $0.88 (0.25%) |
| Ex-Dividend Date | Jul 29, 2026 |
| Volume | 541,791 |
| Open | 343.87 |
| Previous Close | 344.25 |
| Day's Range | 341.68 - 351.96 |
| 52-Week Range | 223.83 - 386.00 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 405.38 (+17.08%) |
| Earnings Date | Oct 22, 2026 |
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2025, WST's revenue was $3.07 billion, an increase of 6.25% compared to the previous year's $2.89 billion. Earnings were $493.70 million, an increase of 0.20%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for WST stock is "Strong Buy." The 12-month stock price target is $405.38, which is an increase of 17.08% from the latest price.
News
West Pharmaceutical Services Transcript: Wells Fargo 21st Annual Healthcare Conference
Leadership transition is expected to accelerate growth initiatives and customer engagement. Q2 results beat expectations, prompting raised guidance and margin expansion, driven by HVP components, biologics, and GLP-1s. Investments focus on high-value solutions and capital efficiency.
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will prese...
West Pharmaceutical Services Earnings Call Transcript: Q2 2026
Q2 2026 saw double-digit revenue and EPS growth, driven by strong HVP components and biologics demand, with robust performance across all geographies. Full-year guidance was raised, reflecting high teens growth in HVP components and continued margin expansion.
West Pharmaceutical Services Earnings release: Q2 2026
West Pharmaceutical Services released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
West Pharmaceutical Services Slides: Q2 2026
West Pharmaceutical Services has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
West Pharmaceutical Services Quarterly report: Q2 2026
West Pharmaceutical Services has published its Q2 2026 quarterly earnings report on July 23, 2026.
West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
West Pharmaceutical Services raised its annual profit and revenue forecasts on Thursday as strong demand for components used in injectable drugs, including diabetes and obesity treatments, helped it...
West Reports Second-Quarter 2026 Results
Raising Full-Year Net Sales and EPS guidance EXTON, Pa., July 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutio...
West Declares Quarterly Dividend
EXTON, Pa., July 21, 2026 /PRNewswire/ -- On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug admini...
West to Host Second-Quarter 2026 Conference Call
EXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will releas...
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the company complet...
West Pharmaceutical Services Transcript: 46th Annual William Blair Growth Stock Conference
Strong growth in high-value injectable medicine components, driven by biologics, GLP-1s, and regulatory changes, is fueling double-digit margin and EPS expansion. Leadership transition to a new CEO aligns with strategic growth, supported by robust cash flow and global market presence.
West Pharmaceutical Services Slides: 46th Annual William Blair Growth Stock Conference
West Pharmaceutical Services has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
West Pharma names former Thermo Fisher executive Lagarde as CEO
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel Lagarde as its top boss, effective August 31, succeeding longtime chief Eric Green.
West Appoints Michel Lagarde to be President and Chief Executive Officer
Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a ...
West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast
West Pharmaceutical Services said on Wednesday it has restored operations across its sites after a cybersecurity attack earlier this month and expects the incident to have no material impact on its ...
West Pharma says operations recovering after cyberattack
West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack earlier this month disrupted manufacturing and logistics globally.
West Pharmaceutical Services Transcript: Bank of America Global Healthcare Conference 2026
A recent cybersecurity breach was contained with minimal disruption, and operations are being restored methodically. Strong Q1 results were driven by robust demand for HVP components, GLP-1s, and regulatory changes, supporting raised guidance and long-term growth expectations.
West Pharmaceutical Services Transcript: AGM 2026
The meeting covered board elections, executive compensation, auditor ratification, and a shareholder proposal for an independent board chair, which was not approved. All director nominees were reelected and executive pay was endorsed by a majority.
West Pharmaceutical Services Earnings Call Transcript: Q1 2026
Q1 2026 delivered 21% revenue growth and 47% higher adjusted EPS, driven by strong HVP component and biologics demand. Full-year guidance was raised for both revenue and EPS, with operational excellence and global regulatory trends supporting continued momentum.
West Pharmaceutical Services Slides: Q1 2026
West Pharmaceutical Services has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
West Pharmaceutical Services Earnings release: Q1 2026
West Pharmaceutical Services released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
West Pharmaceutical Services Quarterly report: Q1 2026
West Pharmaceutical Services has published its Q1 2026 quarterly earnings report on April 23, 2026.
West Pharma lifts 2026 profit forecast on strong demand for medical equipment
West Pharmaceutical on Thursday raised its annual profit and revenue forecasts after beating estimates for first-quarter results, betting on strong demand for its proprietary products that include sy...
West Reports First-Quarter 2026 Results
Strong Start to the Year and Raising Full-Year Revenue and EPS guidance EXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, hig...